NYSE:TFX - Teleflex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $384.92
  • Forecasted Upside: 52.59 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$252.25
▼ -2.84 (-1.11%)

This chart shows the closing price for TFX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teleflex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TFX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TFX

Analyst Price Target is $384.92
▲ +52.59% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Teleflex in the last 3 months. The average price target is $384.92, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 52.59% upside from the last price of $252.25.

This chart shows the closing price for TFX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Teleflex. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/5/2022Wolfe ResearchInitiated CoverageOutperformN/A
5/23/2022Truist FinancialLower Price TargetHold$340.00 ➝ $317.00Low
5/23/2022Royal Bank of CanadaLower Price Target$390.00 ➝ $380.00Low
5/9/2022Bank of AmericaInitiated CoverageNeutral$315.00High
4/29/2022Truist FinancialLower Price Target$370.00 ➝ $340.00Medium
4/12/2022Truist FinancialInitiated CoverageHold$370.00Medium
2/25/2022Morgan StanleyLower Price TargetEqual Weight$383.00 ➝ $378.00High
2/24/2022Piper SandlerBoost Price Target$320.00 ➝ $335.00Medium
2/23/2022Raymond JamesLower Price TargetOutperform$391.00 ➝ $370.00Low
1/31/2022Needham & Company LLCLower Price TargetBuy$425.00 ➝ $400.00Low
1/21/2022Piper SandlerLower Price Target$325.00 ➝ $320.00Low
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$431.00 ➝ $383.00High
1/4/2022Piper SandlerDowngradeOverweight ➝ Neutral$465.00 ➝ $325.00Low
12/13/2021Wells Fargo & CompanyLower Price TargetOverweight ➝ Overweight$450.00 ➝ $355.00Medium
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$415.00Low
10/29/2021Morgan StanleyLower Price TargetOverweight$478.00 ➝ $431.00Low
10/29/2021Raymond JamesLower Price TargetOutperform$440.00 ➝ $391.00Low
10/29/2021JMP SecuritiesLower Price TargetMarket Outperform$470.00 ➝ $430.00High
9/10/2021Jefferies Financial GroupInitiated CoverageBuy$485.00Medium
9/7/2021Raymond JamesInitiated CoverageBuy$440.00Low
8/2/2021KeyCorpLower Price TargetOverweight$448.00 ➝ $439.00Low
7/30/2021JMP SecuritiesReiterated RatingMarket OutperformMedium
7/30/2021SVB LeerinkBoost Price TargetMarket Perform$410.00 ➝ $415.00Low
7/19/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$485.00 ➝ $410.00High
7/9/2021Needham & Company LLCInitiated CoverageBuy$486.00Low
6/2/2021Jefferies Financial GroupReiterated RatingBuy$485.00Medium
5/23/2021SVB LeerinkReiterated RatingBuyLow
4/30/2021Morgan StanleyBoost Price TargetOverweight$450.00 ➝ $478.00Medium
4/30/2021SVB LeerinkBoost Price TargetOutperform$475.00 ➝ $485.00Medium
3/12/2021Raymond JamesBoost Price TargetStrong-Buy$460.00 ➝ $480.00Medium
2/26/2021Raymond JamesBoost Price TargetStrong-Buy$440.00 ➝ $460.00Low
2/25/2021Piper SandlerReiterated RatingOverweight$405.00 ➝ $465.00Medium
1/27/2021JMP SecuritiesBoost Price TargetMarket Outperform$375.00 ➝ $440.00Low
1/11/2021Wells Fargo & CompanyBoost Price TargetOverweight$425.00 ➝ $455.00Medium
1/8/2021KeyCorpBoost Price TargetOverweight$382.00 ➝ $441.00Medium
1/6/2021Needham & Company LLCBoost Price TargetBuy$406.00 ➝ $445.00N/A
12/15/2020Morgan StanleyBoost Price TargetOverweight$375.00 ➝ $450.00Low
12/15/2020UBS GroupBoost Price TargetBuy$435.00 ➝ $455.00High
12/15/2020SVB LeerinkBoost Price TargetOutperform$415.00 ➝ $450.00High
12/3/2020Raymond JamesBoost Price TargetStrong-Buy$400.00 ➝ $440.00Low
11/2/2020KeyCorpUpgradeSector Weight ➝ Overweight$382.00Low
10/30/2020Piper SandlerLower Price Target$420.00 ➝ $405.00High
10/30/2020Morgan StanleyLower Price TargetOverweight$400.00 ➝ $375.00Medium
10/30/2020Raymond JamesLower Price TargetStrong-Buy$440.00 ➝ $400.00High
10/30/2020SVB LeerinkLower Price TargetOutperform$430.00 ➝ $415.00High
8/28/2020Raymond JamesReiterated RatingBuyMedium
7/31/2020Raymond JamesBoost Price TargetStrong-Buy$400.00 ➝ $440.00Low
7/31/2020Morgan StanleyBoost Price TargetOverweight$380.00 ➝ $400.00Medium
6/4/2020SVB LeerinkBoost Price TargetTop Pick ➝ Outperform$400.00 ➝ $425.00Low
5/1/2020UBS GroupLower Price TargetBuy$440.00 ➝ $410.00High
5/1/2020JMP SecuritiesLower Price TargetMarket Outperform$395.00 ➝ $385.00Medium
5/1/2020Wells Fargo & CompanyBoost Price TargetOverweight$365.00 ➝ $375.00High
5/1/2020Morgan StanleyBoost Price TargetOverweight$350.00 ➝ $380.00Medium
5/1/2020Raymond JamesBoost Price TargetStrong-Buy$360.00 ➝ $400.00Medium
5/1/2020Piper SandlerLower Price TargetOverweight$425.00 ➝ $375.00Medium
4/30/2020Needham & Company LLCReiterated RatingBuy$431.00Medium
4/3/2020Raymond JamesLower Price TargetStrong-Buy$450.00 ➝ $360.00Low
3/27/2020Morgan StanleyLower Price TargetOverweight$405.00 ➝ $350.00Medium
3/23/2020StephensLower Price TargetOverweight$425.00 ➝ $275.00High
2/24/2020BarclaysReiterated RatingHold$365.00 ➝ $378.00Medium
2/21/2020Piper SandlerBoost Price Target$425.00 ➝ $400.00Low
2/21/2020StephensBoost Price TargetOverweight$400.00 ➝ $425.00High
2/21/2020Raymond JamesBoost Price TargetStrong-Buy$415.00 ➝ $450.00High
2/21/2020UBS GroupBoost Price TargetBuy$430.00 ➝ $440.00High
1/31/2020Needham & Company LLCBoost Price TargetBuy$408.00 ➝ $423.00High
1/17/2020Wells Fargo & CompanyBoost Price TargetOverweight$415.00 ➝ $425.00Low
12/18/2019UBS GroupBoost Price TargetBuy$415.00 ➝ $430.00Medium
12/17/2019Morgan StanleyBoost Price TargetOverweight$392.00 ➝ $405.00Low
11/1/2019BarclaysSet Price TargetHold$356.00 ➝ $365.00N/A
10/15/2019Needham & Company LLCSet Price TargetBuy$403.00Low
10/7/2019Raymond JamesLower Price TargetStrong-Buy$420.00 ➝ $415.00Low
9/4/2019SVB LeerinkBoost Price TargetOutperform$395.00 ➝ $405.00Medium
8/5/2019BarclaysBoost Price TargetEqual Weight$309.00 ➝ $356.00Low
8/5/2019JMP SecuritiesBoost Price TargetMarket Outperform$325.00 ➝ $395.00Medium
8/2/2019Raymond JamesBoost Price TargetStrong-Buy$350.00 ➝ $420.00Low
8/2/2019Morgan StanleyBoost Price TargetOverweight$345.00 ➝ $392.00Low
8/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$325.00 ➝ $403.00Low
7/16/2019Morgan StanleyBoost Price TargetOverweight$320.00 ➝ $345.00Low
6/11/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$345.00Low
4/24/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$325.00Low
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $309.00Low
3/27/2019Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$320.00 ➝ $348.00Medium
3/26/2019Needham & Company LLCReiterated RatingBuy$325.00Medium
3/22/2019UBS GroupBoost Price TargetBuy$350.00Low
2/26/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$305.00 ➝ $315.00Low
2/22/2019BarclaysSet Price TargetHold$287.00Medium
2/22/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$300.00 ➝ $325.00High
1/2/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$295.00 ➝ $305.00Medium
11/27/2018UBS GroupInitiated CoverageBuy$310.00High
11/2/2018Piper Jaffray CompaniesBoost Price TargetOverweight$310.00Medium
11/2/2018Needham & Company LLCReiterated RatingBuy$315.00High
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$266.00Low
9/10/2018Needham & Company LLCUpgradeBuy ➝ Strong-Buy$279.00 ➝ $300.00High
8/3/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$310.00 ➝ $295.00Medium
8/3/2018Needham & Company LLCLower Price TargetBuy$298.00 ➝ $279.00Medium
6/5/2018SVB LeerinkBoost Price TargetOutperform$309.00 ➝ $317.00Medium
5/15/2018Needham & Company LLCBoost Price TargetBuy$293.00 ➝ $298.00Medium
5/9/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$293.00 ➝ $298.00Low
5/4/2018Deutsche Bank AktiengesellschaftSet Price TargetHold ➝ Hold$251.00 ➝ $255.00Low
5/3/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $293.00Medium
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$257.00Low
2/23/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$321.00 ➝ $300.00High
1/30/2018SVB LeerinkReiterated RatingBuy$307.00 ➝ $321.00High
1/18/2018StephensReiterated RatingBuy$300.00High
11/14/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$251.00N/A
11/10/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$295.00N/A
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$274.00 ➝ $290.00N/A
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$270.00 ➝ $295.00N/A
11/3/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$237.00 ➝ $285.00N/A
9/25/2017StephensReiterated RatingBuy$230.00 ➝ $270.00Low
9/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$238.00 ➝ $251.00Low
9/12/2017BarclaysReiterated RatingOverweight$230.00 ➝ $253.00Low
9/8/2017Jefferies Financial GroupBoost Price TargetBuy$253.00 ➝ $270.00High
9/7/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$227.00 ➝ $266.00High
9/6/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$220.00 ➝ $274.00Low
9/6/2017KeyCorpReiterated RatingHoldHigh
9/5/2017Needham & Company LLCBoost Price TargetBuy$228.00 ➝ $237.00Low
8/9/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$220.00 ➝ $238.00Low
8/9/2017Jefferies Financial GroupReiterated RatingBuy$230.00 ➝ $253.00Low
8/4/2017Needham & Company LLCReiterated RatingBuyMedium
8/3/2017Jefferies Financial GroupReiterated RatingBuy$230.00High
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/7/2021
  • 4 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 4 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/6/2022
  • 7 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 6 very positive mentions
  • 27 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/5/2022
  • 6 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Teleflex logo
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $252.25
Low: $246.51
High: $252.63

50 Day Range

MA: $272.54
Low: $244.93
High: $316.18

52 Week Range

Now: $252.25
Low: $244.81
High: $428.36

Volume

267,319 shs

Average Volume

334,283 shs

Market Capitalization

$11.83 billion

P/E Ratio

24.51

Dividend Yield

0.53%

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Teleflex?

The following Wall Street sell-side analysts have issued reports on Teleflex in the last twelve months: Bank of America Co., Jefferies Financial Group Inc., JMP Securities, KeyCorp, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TheStreet, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for TFX.

What is the current price target for Teleflex?

0 Wall Street analysts have set twelve-month price targets for Teleflex in the last year. Their average twelve-month price target is $384.92, suggesting a possible upside of 52.6%.
View the latest price targets for TFX.

What is the current consensus analyst rating for Teleflex?

Teleflex currently has 5 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TFX will outperform the market and that investors should add to their positions of Teleflex.
View the latest ratings for TFX.

How do I contact Teleflex's investor relations team?

Teleflex's physical mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company's listed phone number is (610) 225-6800 and its investor relations email address is [email protected] The official website for Teleflex is www.teleflex.com. Learn More about contacing Teleflex investor relations.